Amador Bioscience, a US-based, full-service CRO with global expertise in translational research and clinical development, announced on Friday that it has named Dr Lorin Roskos as its new chief scientific officer (CSO) and president of Quantitative Clinical Pharmacology (QCP).

Dr Roskos brings a wealth of experience in clinical pharmacology, pharmacometrics, systems pharmacology, and translational medicine to Amador Bioscience. Throughout his career, Dr Roskos has served in senior executive roles across research, nonclinical and clinical development at global pharmaceutical and small biotechnology companies including Amgen, AstraZeneca, and Exelixis. In his new role, Dr Roskos will help establish Amador's scientific leadership in the industry, lead the development and implementation of Amador's global clinical pharmacology strategy, advance company capabilities, and expand growth opportunities across the company's business segments.